Cannabidivarin

Cannabidivarin

SCHEMBL19477708

C=C(C)C1CCC(C)=CC1c1c(O)cc(CCC)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 12/20 1.00
CNR1 P21554 11/20 1.00
OPRM1 P35372 7/20 1.00
GPR55 Q9Y2T6 4/20 1.00
TRPV1 Q8NER1 3/20 1.00
CYP1A1 P04798 2/20 1.00
CYP2D6 P10635 2/20 1.00
CYP2B6 P20813 2/20 1.00
SLC6A2 P23975 2/20 1.00
CYP2C19 P33261 2/20 1.00
SLC6A3 Q01959 2/20 1.00
TRPM8 Q7Z2W7 2/20 1.00
TRPA1 O75762 1/20 1.00
GPR6 P46095 1/20 1.00
NAAA Q02083 1/20 1.00
TRPV3 Q8NET8 1/20 1.00
TRPV4 Q9HBA0 1/20 1.00
DAGLA Q9Y4D2 1/20 1.00
TRPV2 Q9Y5S1 1/20 1.00
MLNR O43193 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cannabidivarin SCHEMBL22705595 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL18371742 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL17345387 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL2759238 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL243338 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL16224876 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL6857317 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL10296698 0.93 CNR2 (0.86) CNR2CNR1OPRM1GPR55TRPV1
SCHEMBL23686658 0.92 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
SCHEMBL22705457 0.92 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240269153-A1 BIOACTIVE BIPHASIC COMPOSITIONS NATURAL EXTRACTION SYS LLC (US) 2024-08-15 US claimed
US-20240131040-A1 COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS Natural Extraction Systems, LLC (US) 2024-04-25 US claimed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO claimed
US-20230073802-A1 COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS Natural Extraction Systems, LLC (US) 2023-03-09 US claimed
WO-2022251709-A1 BIOACTIVE BIPHASIC COMPOSITIONS Natural Extraction Systems, LLC (US) 2022-12-01 WO claimed
WO-2022173812-A1 COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS Natural Extraction Systems, LLC (US) 2022-08-18 WO claimed
WO-2022173901-A1 COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS Natural Extraction Systems, LLC (US) 2022-08-18 WO claimed
WO-2021158714-A1 COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20260083161-A1 CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS NATURAL EXTRACTION SYS LLC (US) 2026-03-26 US disclosed
US-12484606-B2 Compositions and methods related to anionic cannabinoid molecules Natural Extraction Systems, LLC (US) 2025-12-02 US disclosed
US-20250090494-A1 CANNABIDIOL COMPOSITIONS HAVING MODIFIED CANNABINOID PROFILES NORAMCO, LLC 2025-03-20 US disclosed
US-20240269153-A1 BIOACTIVE BIPHASIC COMPOSITIONS NATURAL EXTRACTION SYS LLC (US) 2024-08-15 US disclosed
EP-3763361-B1 CANNABIDIVARIN (CBDV) FOR USE IN THE TREATMENT OF EPILEPSY GW PHARMA LTD (GB) 2024-06-26 EP disclosed
WO-2024112694-A1 RECOMBINANT POLYPEPTIDES WITH PRENYLTRANSFERASE ACTIVITY FOR BIOSYNTHESIS OF CANNABINOIDS AND HOP COMPOUNDS WILLOW BIOSCIENCES, INC. (CA) 2024-05-30 WO disclosed
WO-2020123976-A1 COMPOSITIONS AND METHODS RELATED TO ANIONIC CANNABINOID MOLECULES Natural Extraction Systems, LLC (US) 2020-06-18 WO disclosed
WO-2020123809-A1 COMPOSITIONS AND METHODS RELATED TO ANIONIC CANNABINOID MOLECULES Natural Extraction Systems, LLC (US) 2020-06-18 WO disclosed
WO-2019180706-A1 METHODS AND COMPOSITIONS FOR TREATING EPILEPSY AND ASSOCIATED DISORDERS BOL PHARMA LTD. (IL) 2019-09-26 WO disclosed
EP-2782563-B1 TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES GW PHARMA LTD (GB) 2018-04-25 EP disclosed
US-9815810-B1 Method of cannabinoid preservation through crystallization and other crystal structures Deep Cell Industries Inc. (US) 2017-11-14 US disclosed
WO-2017178807-A1 USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA GW Research Limited (GB) 2017-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250090494-A1 CANNABIDIOL COMPOSITIONS HAVING MODIFIED CANNABINOID PROFILES MGLL, CNR2, HDHD5 CNR2 2/4885CNR1 4/4885OPRM1 40/4885
US-20260083161-A1 CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS CNR2, CNR1, OPRD1 CNR2 1/4885CNR1 2/4885OPRM1 4/4885
US-12484606-B2 Compositions and methods related to anionic cannabinoid molecules CNR2, CNR1, PHOSPHO1 CNR2 1/4885CNR1 2/4885OPRM1 12/4885
US-20240131040-A1 COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS CNR1, CNR2, OPRD1 CNR2 2/4885CNR1 1/4885OPRM1 5/4885
US-20230073802-A1 COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS CNR2, CNR1, FAAH CNR2 1/4885CNR1 2/4885OPRM1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.